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Preventing cervical cancer using HPV
self-sampling: direct mailing of test-kits
increases screening participation more than
timely opt-in procedures - a randomized
controlled trial
Mette Tranberg1,2* , Bodil Hammer Bech3, Jan Blaakær4,5, Jørgen Skov Jensen6, Hans Svanholm1,7
and Berit Andersen1,2
Abstract
Background: Cervical cancer screening participation remains insufficient in most countries. Our aim was to evaluate
whether offering a HPV self-sampling kit, either mailed directly to the woman’s home or using timely opt-in procedures
for ordering the kit, increased screening participation compared with a standard second reminder.
Methods: In this randomized, controlled effectiveness trial, 9791 Danish women aged 30–64 who were due to receive
the second reminder were equally randomized to either: 1) direct mailing of a second reminder and a self-sampling kit
(directly mailed group); 2) mailing of a second reminder that offered a self-sampling kit to be ordered by e-mail, text
message, phone, or webpage (opt-in group); or 3) mailing of a second reminder to attend regular cytology screening
(control group). In an intention-to-treat analysis, we estimated the participation rate at 180 days post intervention, by
returning a self-sample or attending regular cytology screening. We calculated the proportion of women with a
positive HPV self-sample who attended for cervical cytology triage at the general practitioner within 90 days.
Results: Participation was significantly higher in the directly mailed group (38.0%) and in the opt-in group (30.9%) than
in the control group (25.2%) (participation difference (PD): 12.8%, 95% CI: 10.6–15.0% and PD: 5.7%, 95% CI: 3.5–7.9%,
respectively). Within 90 days, 107 women (90.7%, 95% CI: 83.9–95.3%) with a HPV-positive self-sample
attended follow-up.
Conclusions: Offering the opportunity of HPV self-sampling as an alternative to regular cytology screening
increased participation; the direct mailing strategy was the most effective invitation strategy. A high compliance with
follow-up was seen.
Trial registration: Current Controlled Trials NCT02680262. Registered 10 February 2016.
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Background
Organized screening programs have contributed to a
decline in cervical cancer incidence and mortality in
many Western countries [1–3]. The magnitude of the
preventive effect of cervical cancer screening depends
on high participation and coverage, as well as timely
follow-up and treatment of premalignant lesions [4, 5].
However, more than half of all invasive cervical cancers
diagnosed in countries with organized screening pro-
grams arise among under- or unscreened women [6–8];
thus, targeting non-participating women is crucial.
Common barriers to cervical cancer screening include
discomfort during the pelvic examination and inconveni-
ent appointment times [9, 10]. The on-going introduc-
tion of high-risk human papillomavirus (hrHPV) testing
in cervical cancer screening [11, 12] now makes it pos-
sible to overcome these barriers by offering women a
test-kit for home-based cervico-vaginal self-sampling for
hrHPV testing (HPV self-sampling). Self-samples have
shown a sensitivity in detecting cervical intraepithelial
neoplasia grade 2+ (CIN2+) that is similar to that of
clinician-collected samples, provided that certain validated
PCR based HPV DNA tests are used [13, 14]. Generally,
self-sampling enjoys acceptance among women [15].
Mailing self-sampling kits directly to women’s home
addresses has been shown to improve participation in
cervical cancer screening compared to the regular
screening invitation/reminder [16], with participation
rates ranging from 10% to 39% among underscreened
women [17, 18]. To minimize the number of wasted kits
and associated costs, other trials [19–21] have explored
the effect of offering opt-in self-sampling, i.e. receiving
an invitation to actively order the kit by phone [20], by
ordinary mail [19], or by picking it up at the pharmacy
[21]. The results of these trials are mixed; one trial re-
ported a 13.9% increase in participation among long-
term non-participants [19], while two other trials found
no positive effect [20, 21]. The opt-in strategy may be
more effective if the kit can be ordered electronically
via e-mail request, webpage, or text message (i.e. timely
opt-in procedures) owing to greater convenience. How-
ever, one cluster-randomized trial showed no effect on
participation among young women, although the kit
could be requested by e-mail and text message [22].
Thus, more trials are warranted to explore the effect-
iveness of timely opt-in procedures and direct mailing
of the kit before implementing the optimal self-
sampling invitation strategy to increase screening
participation in organized programs. Furthermore, a
HPV-positive self-sampling result should be accompan-
ied by appropriate follow-up to make the screening
offer beneficial, but compliance to follow-up after a
HPV-positive self-sampling result has varied widely
(range 41 to 100%) [19, 23].
Within the context of a routinely organized screening
program, our aim was to compare the effect on screen-
ing participation of mailing a self-sampling kit directly
to women and timely opt-in procedures for ordering the
kit as compared with the standard second reminder for
regular cytology screening. We also estimated the pro-
portion of women with a HPV-positive self-sample
undergoing the recommended follow-up testing.
Methods
The present study was conducted in line with the protocol
of the CHOiCE (Cervical HOme-based CancEr screening)
trial published elsewhere [24]. The report of this clinical
trial conforms to the CONSORT statement [25].
Design and study setting
CHOiCE was a randomized, controlled, effectiveness
population-based trial, nested in the Danish organized
cervical cancer screening program conducted in the
Central Denmark Region between March 2016 and
May 2017 [24]. This region is a mixed rural and urban
area, covering approximately one-fourth of the Danish
population [26].
In Denmark, cervical cancer screening is organized as
a nationwide integrated program. The program is based
on a call-recall system using data from the invitation
module in the Danish Pathology Data Bank (DPDB)
[27]. This module keeps track of women who are due to
receive invitations and reminders to participate in
screening, and it contains information on women who
are no longer subscribed to the screening program, e.g.
due to hysterectomy. Routinely, all pathology specimens
including cervical cytology results, HPV test results, and
histological diagnoses from cervical biopsies are re-
corded in the DPDB using women’s unique civil personal
registration (CPR) number [28, 29].
Danish women are recommended to participate in the
screening program every third year when aged 23–
49 years and every fifth year when aged 50–64 years
[30], but opportunistic testing is frequent [31]. Based on
their screening status in the DPDB, only women not reg-
istered with a cervical cytology sample within the rec-
ommended time interval are invited for screening. The
invitation is sent to the woman’s home address advising
her to book an appointment to have a liquid-based cer-
vical cytology specimen collected by her general practi-
tioner (GP) [30]. Hereafter, liquid-based cervical cytology
is referred to as cervical cytology.
The cervical cytology specimen is mailed to the local
department of pathology for analysis. If no cervical cy-
tology is registered in the DPDB, up to two reminders
will be sent at 3 and 6 months after the initial invitation
[30]. If no cervical cytology is taken within 3 or 5 years
after the initial invitation, the woman is sent a new
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invitation in the next screening round, unless she has ac-
tively opted out of the screening program. In Denmark,
screening and treatment are provided free of charge.
In the Central Denmark Region, the Department of
Pathology, Randers Regional Hospital analyzes all sam-
ples obtained in connection with the Cervical Cancer
Screening Program. Invitations and reminders are rou-
tinely handled by the Department of Public Health
Programs, Randers Regional Hospital [24].
Study population and randomization
Included in the study were women aged 30 to 64 years
who were due to receive the second reminder from the
Central Denmark Region between March 7th 2016 and
August 8th 2016. All eligible women were identified on
a weekly basis in the invitation module in the DPDB,
and no exclusion criteria were used.
Web-based computer randomization in RedCap was
used to allocate eligible women to the three groups of
the trial at a 1:1:1 ratio by the method of individual
randomization with randomly varying block sizes of 3, 6,
and 9 [32]. The randomization list was produced by an
independent programmer who was not otherwise in-
volved in the trial. The women were unaware of the
randomization, but blinding of the participants and
study staff was impossible due to the nature of the
interventions.
Interventions
Women in the directly mailed group received a modified
second reminder, a leaflet, and a self-sampling kit. The
modified second reminder informed of the possibility of
collecting a self-sample, but also about the possibility of
having a cervical cytology specimen taken at the GP
[24]. The kit included a brush device (Evalyn® Brush,
Rovers Medical Devices B.V, Oss, Netherlands) to collect
a cervico-vaginal sample for subsequent hrHPV testing
[33]. The kit also included instructions describing how
to obtain and mail the sample as well as a pre-stamped
return envelope addressed to the Department of
Pathology, Randers Regional Hospital, which performed
the hrHPV testing [24].
Except for the kit, women in the opt-in group re-
ceived the same material as those in the directly
mailed group [24]. Additionally, the leaflet for this
group held information describing how to order the
kit by e-mail, text message, phone, or via a study web-
page (www.hjemme-us.rm.dk) [24]. After receiving the
orders in our department, the self-sampling kit was
mailed to the women within 2 to 4 working days.
Women in the control group received a standard sec-
ond reminder that informed them about the current test
opportunity [24]. The reminder contained no informa-
tion about self-sampling [24]. All study material was
written in Danish. Throughout the study, a telephone
helpline and a webpage with information for the GPs
were available. Figure 1 shows the study design.
Analyses of samples
Upon arrival at the Department of Pathology, the dry
brush head was placed in 10 ml of SurePath medium
(BD Diagnostics, Burlington, NC), stored overnight,
and then vortexed for 5 min. Following this, 2 ml of
the medium was placed in a test tube, which was the
starting point for hrHPV testing. The brush specimens
were tested for hrHPV using the clinically validated
and Federal Drug Agency (FDA)-approved Cobas® 4800
HPV DNA test (Roche Diagnostics, GmBH, Switzerland),
according to the manufacturer’s instructions. This test is
designed to detect HPV16, HPV18, and 12 other hrHPV
types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) in a
single pool [34]. Results were either 1) hrHPV negative, 2)
Fig. 1 Flow chart of the study design. Abbreviations: HPV self-sampling: HPV SS. GP: General Practitioner.*) Also had the possibility of attending a
GP for regular cytology screening
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hrHPV positive (HPV16, HPV18 and/or other hrHPV
types), or 3) invalid [24]. The hrHPV test results of the
self-samples were registered in the DPDB [24].
Cervical cytology specimens obtained by GPs were
taken with a cervical brush, stored in 10 ml SurePath
medium (BD Diagnostics, Burlington, NC), and mailed
to the Department of Pathology. The specimens were
analyzed using the standard procedure in the Central
Denmark Region [30], i.e. relying on cervical cytology
using the Bethesda nomenclature for control group
women aged 30–59 years. Women with ASC-US have re-
flex Cobas® 4800 (Roche Diagnostics, GmBH, Switzerland)
hrHPV triage. For women aged 60–64 years, the primary
analysis was hrHPV testing using the Cobas® 4800 (Roche
Diagnostics, GmBH, Switzerland) test, followed by cy-
tology to triage women positive for other hrHPV types
than HPV16/18 for onward referral. Women positive for
HPV16/18 were referred directly to colposcopy, whereas
hrHPV-negative women left the screening program.
Follow-up algorithm after self-sampling
Test results and follow-up recommendations for the
self-samples were mailed to the women and their GPs,
unless the woman had rejected that option.
Women with a hrHPV-positive self-sample test result
were advised to visit their GP for a cervical cytology tri-
age specimen within 30 days [24]; after this, the GP
should handle the women as described in Danish routine
guidelines, i.e. women with abnormal cervical cytologies
(threshold ASC-US and hrHPV positive or LSIL, or
ASC-H or HSIL or AGC, or AIS or malign tumor cells)
should be referred to a gynecologist for colposcopy
within 3 months, women with normal cervical cytologies
were invited for a cervical cytology sample and hrHPV
retesting after 12 months, and women with inadequate
cervical cytologies were recommended to have a new
cytology sample taken within 2 to 4 months [30]. At
colposcopy in a gynecological clinic, cervical lesions
should be biopsied and/or treated according to routine
Danish guidelines and sent to the Department of
Pathology, which classifies the samples using the CIN
nomenclature [30].
In cases with a hrHPV-negative self-sampling test re-
sult, the women were referred back to the national
screening program with a recommendation to partici-
pate in the next screening round. Women with an in-
valid self-sample received a second self-sampling kit and
were encouraged to repeat self-sampling at home or to
visit a GP for regular cytology screening [24].
Outcomes
The primary outcome was the participation rate, i.e. the
percentage of randomized women who returned a self-
sample or attended regular cytology screening at their
GP within 180 days (i.e. 6 months) post second reminder
[24]. Secondary outcomes included the prevalence of
hrHPV among self-samplers and the percentage of
women with an hrHPV-positive self-sample having a
recommended follow-up. Follow-up was defined as at-
tending a GP for a cervical cytology triage sample within
30, 60, or 90 days [24]. Further outcomes measured were
use of the different opt-in procedures and the propor-
tion of histologically confirmed CIN2+ lesions (including
CIN2, CIN3/AIS and carcinoma) in the three groups.
Categorization of the histological diagnosis was based on
the most severe diagnosis if further histological diagnosis
was available.
Sample size
The sample size was determined based on the ability
to detect differences of 3.6% in the participation rate
between the intervention groups and the control
group [35]. To achieve a statistical power of 80%
while assuming that the participation rate in the con-
trol group was 28.7% [36], we had to include at least
3109 women in each group (a total of 9327 women)
[24]. Kits and reminders were sent out progressively
on a weekly basis, and this process was to continue
until at least 9327 women had been included in the
study [24].
Classification of screening history
Each woman’s screening history over the previous
15 years was determined through linkage to the DPDB
using data from January 1th 2001 to March 7th 2016.
All registered cervical cytology samples in the period
were included in the analysis. We calculated if a woman
had participated in the previous screening round and we
registered the number of cervical cytology samples
during the previous 15 years. Women aged 29 to 49 and
50 to 64 years at the time of initial invitation (i.e.
6 months prior to the age at the time of the second re-
minder) were defined as having been screened in the
previous screening round if a cervical cytology result
had been registered within the past 3.5 years and
5.5 years, respectively.
Women aged 30 to 34 years (7 to 11 years of screening
history) or 56 to 64 years (15 years of screening history)
were defined as “regularly screened” if ≥2 cervical cy-
tology samples were registered, and as “underscreened”
if they had only one cervical cytology sample regis-
tered. Women aged 35 to 55 years (12 to 15 years of
screening history) were defined as “regularly screened”
if ≥3 cervical cytology samples were registered, and as
“underscreened” if they had only one or two cervical
cytology sample(s) registered. Women in all ages were
defined as being “unscreened” if no cervical cytology
sample was registered.
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Statistical analysis
Descriptive statistics (numbers and proportions) were
used to compare the baseline characteristics of the
women in the intervention groups and the control
group. The participation rate in each group was calcu-
lated using intention-to-treat analysis. Participation rates
in the directly mailed group and the opt-in group were
compared to those of the control group by estimating
both the absolute difference in participation rate (PD)
and the ratio followed by 95% confidence intervals (CIs).
The analyses were also stratified by age and screening
history. We estimated the hrHPV prevalence among
self-samplers and the number of histologically confirmed
CIN2+ lesions in the groups. Estimates and 95% CIs for
the proportion of women attending the recommended
follow-up were calculated.
In a sensitivity analysis, we assessed the impact on the
participation rates of giving women a shorter time frame
to respond to the interventions. Thus, we used 90 days
(instead of 180 days) post second reminder as the cut-
off value to differentiate between participants and non-
participants. This approach is in accordance with the
definition used to determine the participation rate after
the second reminder in the Danish Quality Database for
cervical cancer screening [37].
All analyses were performed using STATA version 13
(College Station, TX: StataCorp LP).
Ethical statement
The study was approved by the Danish Data Protection
Agency (j.no: 1–16–02-495-15) and by the Danish
Health Authorities (j.no: 3–3013-1407/1). Furthermore,
the study achieved clearance at the Central Denmark
Region Committees on Health Research Ethics (j.no: 1–
10–72-259-15). The included women were informed that
if they returned their self-sample they thereby expressed
their consent to the analysis of the sample and to receiving
any test results and follow-up recommendations by mail.
Results
Study population
A total of 9791 women were included in the study and
randomized into three groups: 3265(33.3%) in the
directly mailed group, 3264 (33.3%) in the opt-in
group, and 3262 (33.3%) in the control group (Fig. 1).
The distribution of age and screening history was
similar across the three groups (Table 1).
Participation
A total of 1242 (38.0%) women from the directly mailed
group participated after the second reminder, 635 (19.4%)
by returning the self-sample, while the remaining 607
(18.6%) attended regular cytology screening (Table 2). This
was 12.8% (95% CI: 10.6–15.0%) more than the 25.2% par-
ticipating in the control group. The opt-in strategy re-
sulted in a total participation of 1009 women (30.9%): 270
(8.3%) participated by returning a self-sample, and 739
(22.6%) attended regular cytology screening. Thus, the
total participation in the opt-in group was lower than in
the directly mailed group; still it was significantly higher
than in the control group (PD: 5.7%, 95% CI: 3.5–7.9%)
(Table 2). In all three groups, the participation rate was
lowest for women aged 50–64 years.
Participation in relation to screening history
The offer of self-sampling was effective in motivating
both un- and underscreened women to participate
(Table 2). A higher participation was seen in the directly
mailed group than in the control group among women
who had not participated in the previous screening
Table 1 Baseline characteristics of the study population
Directly mailed group
N = 3265
Opt-in group
N = 3264
Control group
N = 3262
n (%) n (%) n (%)
Age (years)
30–39 1236 (37.9) 1215 (37.2) 1251 (38.4)
40–49 1300 (39.8) 1353 (41.5) 1342 (41.1)
50–64 729 (22.3) 696 (21.3) 669 (20.5)
Screened in the previous screening rounda
Not screened 1298 (39.8) 1272 (38.9) 1249 (38.3)
Screened 1967 (60.3) 1992 (61.0) 2013 (61.7)
Screening historya
Unscreened 604 (18.5) 595 (18.2) 567 (17.4)
Underscreened 802 (24.6) 842 (25.8) 842 (25.8)
Regularly screened 1859 (56.9) 1827 (56.0) 1853 (56.8)
n: Number of randomized women. %: Column percentages. aSee classification of screening history for definitions
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round (PD: 14.9%, 95% CI: 12.2–17.7%). A similar,
though less pronounced, tendency was seen in the opt-
in group (PD: 5.2%, 95% CI: 2.9–7.7%).
Among un- and underscreened women, participation
was significantly higher in the directly mailed group than
in the control group (PD: 12.6 and 12.3%, respectively).
In the opt-in group, we found no significant effect
among unscreened women (PD: 1.5%, 95% CI: -1.6-
4.6%); a significant difference in the participation rate
was found only for underscreened women (PD: 5.7%,
95% CI: 2.1–9.3%).
Effect on the overall participation rate in the screening
program
The overall participation rate after the initial invitation
and the first reminder was estimated to be 58% among
the targeted women: thus, the overall participation after
the invitation and two reminders would reach 74.0%
(95% CI: 73.6–74.4%) in the directly mailed group, 71.0%
(95% CI: 70.6–71.4%) in the opt-in group, and 69.0%
(95% CI: 68.6–69.4%) in the control group. By offering
the possibility of self-sampling to non-participants, the
overall participation rate among invited 30–64 year-old
women would increase by 5.0% (95% CI: 4.8–5.2%)
(from 69.0% to 74.0%) if the direct mailing strategy was
used and by 2.0% (95% CI: 1.9–2.1%) if the opt-in strategy
was used (from 69.0% to 71.0%) (data not shown).
Ordering of the self-sampling kit in the opt-in group
In the opt-in group, the self-sampling kit was ordered
by a total of 409 women of whom 270 (66.0%) returned
the sample within 180 days. Seven women (1.7%) or-
dered the kit but attended a GP for regular cytology
screening, while 132 women (32.3%) ordered the kit
but were not tested within 180 days. The majority of
women ordered the kit through the webpage (70.0%)
or by sending a text message (19.8%). Phone and e-
mail were rarely used (7.8% and 2.4%, respectively)
(data not shown).
HPV prevalence and compliance with follow-up among
self-samplers
Of the 905 self-samples (including samples from both
intervention groups), three samples (0.3%) were invalid
for hrHPV testing, 118 (13.0%, 95% CI: 10.9–15.4%)
were hrHPV positive, and the remaining 784 samples
(86.6%) were hrHPV negative (Table 3). Most women
were positive for other hrHPV types than HPV16/18
(65.2%), followed by HPV16 (12.7%), and HPV18 (9.3%)
(data not shown). The proportion of hrHPV-positive
women decreased with age from 15.7% at age 30–39 to
10.7% at age 50–64 (Table 3).
Compliance with the follow-up cervical cytology triage
sample at the GP within 90 days after a hrHPV-positive
result was 90.7%, (95% CI: 83.9–95.3%). Notably, more
than half (69.5%) of the women attended follow-up
within 30 days after sending the test results and were
therefore compliant with the recommendation (Table 3).
Six women (5.1%) attended follow-up 91–180 days after
receiving the HPV test results, corresponding to an over-
all “long-term” compliance rate of 95.8%, (95% CI. 90.4–
98.6%). Five women (4.2%) without follow-up had not
been screened in the previous screening round and three
were unscreened (data not shown). Most of the non-
compliant women were from the directly mailed group
(n = 4).
Detection of CIN2+
The proportion of CIN2+ lesions per 1000 invited
women was 5.8 (95% CI: 3.5–9.1) in the directly mailed
group and 4.0 (95% CI: 2.1–6.8) in the opt-in group,
compared with 3.1 (95% CI: 1.5–5.6) in the control
group (Table 4). Most of the CIN2+ lesions were found
in women aged < 50 years (data not shown).
For self-samplers, the proportion of CIN2+ lesions
was 20.5 (95% CI: 10.9–34.8) in the directly mailed
group and 18.5 (95% CI: 6.0–42.7) in the opt-in group
per 1000 women screened by self-sampling. In the con-
trol group, the proportion of CIN2+ lesions was 12.2
(95% CI: 5.8–22.2) per 1000 women screened by attending
regular cytology screening (Table 4).
Table 3 HrHPV prevalence and compliance with follow-up in self-samplers, stratified by age groups
HrHPV prevalence Compliance with follow-up within (days) Total
≤ 30 31–60 61–90
N na (%) nb(%) nb(%) nb(%) nb(%)
Age (years)
30–39 312 49 (15.7) 40 (81.6) 2 (4.1) 2 (4.1) 44 (89.8)
40–49 397 48 (12.1) 31 (64.6) 9 (18.8) 4 (8.3) 44 (91.7)
50–64 196 21 (10.7) 11 (52.4) 7 (33.3) 1 (4.8) 19 (90.5)
Total 905 118 (13.0) 82 (69.5) 18 (15.3) 7 (5.9) 107 (90.7)
N: Number of received self-samples. na: Number of women with a hrHPV-positive self-sample. nb: Number of women with a cervical cytology triage sample
%: Row percentages
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Sensitivity analysis
When we used a cut-off value of ≤90 days (instead of
180 days) to differentiate participants from non-
participants, the intervention groups maintained a sig-
nificantly higher participation rate than the control
group (directly mailed: PD: 13.4%, 95% CI: 11.4–15.5%,
and opt in: PD: 4.9%, 95% CI: 3.0–6.9%) (data not
shown).
Discussion
Main findings
In this randomized, controlled effectiveness trial, we
found that directly mailing a HPV self-sampling kit to
women not participating in cervical cancer screening
after an invitation and one reminder resulted in signifi-
cantly higher participation (38.0%) than using a timely
opt-in strategy (30.9%) or a standard second reminder
(25.2%) to approach their GP for regular cytology screening.
Among un- or underscreened women, the direct mailing of
a self-sampling kit proved to be more effective than both
the opt-in strategy and the standard second reminder.
Compliance to follow-up within 90 days among self-
samplers was high (90.7%).
Strengths and limitations
A major strength of this study is the randomized design
that contributes to making the detected differences be-
tween the tested interventions and usual care trustworthy.
Another key strength is the effectiveness approach and
the fact that the study was embedded in an ongoing rou-
tine cervical cancer screening program, which from an im-
plementation point of view provides a reliable and
representative estimate of the expected participation rates
that could be obtained if the possibility of self-sampling
together with the second reminder were to become an op-
tion. Furthermore, we minimized the risk of information
bias and selection problems, firstly, by using data from the
DPDB which has highly valid records on all pathology
specimens for identifying outcomes and, secondly, by
using a population-based design. Additionally, we used
a combination of a clinically validated self-sample de-
vice and a clinically validated PCR-based HPV DNA
test, resulting in a low proportion of invalid self-
samples (< 0.5%).
This trial was not designed to estimate differences in
the proportions of CIN2+ lesions between the interven-
tion groups; thus, observed differences should be inter-
preted with caution.
Comparison with other studies
The participation rate in the directly mailed group
(38.0%) was higher than in other comparable Dutch tri-
als that achieved participation rates of 26.6 to 30.8% at
12 months [38, 39]. This may be explained by the fact
that the Dutch women offered self-sampling were not
informed about the possibility of having regular cytology
screening at their GP. In the opt-in group, the partici-
pation rate (30.9%) was also higher than in previous
opt-in trials that report participation rates of 8.7 to
24.5% [19, 20]. This may be due to different definitions
of non-participants, differences in the time of participa-
tion assessment (range 3 to 12 months), and timely
opt-in procedures which made it easier for women to
participate. Recently, a Danish opt-in study that tar-
geted women being unscreened for ≥4–6 years achieved
a similar participation rate of 30.0%, assessed in a range
of 7 to 18 months [40].
Even though we found participation rates in the inter-
vention groups to be slightly lower among the oldest
women, the possibility of self-sampling increased partici-
pation in all age groups. This suggests that self-sampling
is a suitable strategy across different age groups. It is
expected that implementation of self-sampling in the
Central Denmark Region screening program would in-
crease the overall participation rate among invited
women aged 30–64 years by an extra 2% or 5% for the
opt-in or direct mail strategy, respectively. The latter
figure is similar to the extra 5.2% achieved in a previous
Dutch trial that used direct mailing of the self-sampling
kit together with a second reminder [38].
Almost one third (32.3%) of the women ordering a
self-sampling kit in the opt-in group did not return it.
This suggests that intention to be screened was present,
but something made the women fail to return the sample.
Table 4 Yield of CIN2+ lesions in the intervention and control groups
Directly mailed group
Invited = 3265
Opt-in group
Invited = 3264
Control group
Invited = 3262
Self-sampling Cytology Total Self-sampling Cytology Total Cytology
n n n n n n n
Number screened 635 607 1242 270 739 1009 823
CIN2+ detected 13 6 19 5 8 13 10a
CIN2+ per 1000 invited (95% CI) 4.0 (2.1–6.8) 1.8 (0.7–4.0) 5.8 (3.5–9.1) 1.5 (0.5–3.6) 2.5 (1.1–4.8) 4.0 (2.1–6.8) 3.1 (1.5–5.6)
CIN2+ per 1000 screened (95% CI) 20.5 (10.9–34.8) 9.9 (3.6–21.3) 15.3 (9.2–23.8) 18.5 (6.0–42.7) 10.8 (4.7–21.2) 12.9 (6.9–21.9) 12.2 (5.8–22.2)
CIN2+: CIN2, CIN3/AIS and carcinoma. aOne case of squamous cell carcinoma
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We have no clear explanation for this, but other opt-in
studies have reported a similar tendency (range 11% to
39%) [19, 40]. Thus, both mailing self-sampling kits dir-
ectly and the opt-in procedure result in loss of kits. This
should be taken into consideration when choosing the
self-sampling invitation strategy and the self-sampling de-
vice. Using the webpage and sending a text message were
more commonly used ways of ordering the kit than phone
and e-mail. This result is in line with the Danish opt-in
study, which reported that ordering via a webpage was
considered far more acceptable than ordering by phone or
e-mail (37% vs 1% vs < 1%, respectively) [40].
Among women receiving the self-sampling offer, we
also found that 18.6% of women in the directly mailed
group still chose to approach a GP for a cervical cytology
sample, while this was the case for even more women
(22.6%) in the opt-in group. These findings suggest that
self-sampling may be most effective if it is combined with
other strategies, i.e. not used as the only option.
The effectiveness of self-sampling depends, among
other things, on its capacity to recruit hard-to-reach
women at increased risk of developing cervical cancer.
Our results show that the direct mailing strategy was su-
perior to the opt-in strategy and the standard second re-
minder in terms of higher participation among un- or
underscreened women, but also among women who had
not participated in previous screening rounds. This finding
is supported by other trials that used the direct mail invi-
tation strategy [17, 18]; they report that underscreened
women were more likely to participate when offered self-
sampling (range 10 to 39%) than when sent an invitation/
reminder for regular cytology screening (range 4.5 to
9.0%). Thus, self-sampling may have the potential to re-
duce the earlier documented social inequalities in cervical
cancer screening participation [41]. An up-coming
registry study based on data from this trial will further
explore this issue. These perspectives together with the
cost-effectiveness of self-sampling should also be taken
into account before planning a general rollout of self-
sampling in the routine screening program.
An efficient self-sampling strategy also depends on a
high level of compliance with follow-up among HPV-
positive self-samplers. Compliance with cervical cytology
triage at the GP after a HPV positive self-sample was
high in this trial (90.7%); and when the relatively short
follow-up measure was extended, the “long-term” follow-
up was 95.8% within 180 days. This was higher than was
found in previous Dutch trials that recorded follow-up of
89% to 90% at 18 months with a comparable triage proto-
col [38, 39]. Most importantly, our results show that high
compliance with follow-up could be achieved in a real-
world screening setting without an intensive follow-up
protocol as used in other trials [19, 20]. HrHPV infections
were detected in 13.0% of the self-sampling participants.
This prevalence was higher than was found in an Australian
trial (8.5%) that targeted never- or underscreened women
aged 30–69 years using the same HPV test [42]. The
hrHPV prevalence among self-samplers (13.0%) was
only slightly lower than, but not significantly different
from, the 16.2% observed in a HPV screening study that
included Danish women aged 30–65 years undergoing
regular cytology screening using the Cobas® 4800 HPV
test [43].
Although our trial was not scaled to evaluate the ef-
fect of the self-sampling initiatives on the detection of
CIN2+ lesions, we saw a clear tendency: the proportion
of CIN2+ lesions per 1000 invited women was higher
in the directly mailed and opt-in group than in the con-
trol group. This finding might be interpreted as an
early indicator for the expected impact on cervical can-
cer prevention if self-sampling was to be introduced. It
should be noted that there seemed to be a difference in
CIN2+ detection between the directly mailed and opt-
in group, even though four of the five women who were
not followed up within 180 days were in the directly
mailed group.
The higher detection of CIN2+ among self-sampling
participants than among regular cytology participants in
the control group, also shown in previous trials [44, 45],
may be explained by the fact that primary hrHPV testing
is more sensitive than cytology testing for detecting
CIN2+ [46]. Assuming that the background risk for
CIN2+ is increased among un-or underscreened women
[38], the improved coverage of these women when
self-sampling was offered could be another explan-
ation for the increased CIN2+ detection found among
self-samplers.
Conclusions
Direct mailing of self-sampling kits to non-participating
women was the most effective invitation strategy for in-
creasing participation. Using timely opt-in procedures
yielded a limited participation increase compared with a
standard second reminder to attend regular cytology
screening. Our trial shows that it is feasible to imple-
ment HPV self-sampling into the Danish cervical cancer
screening program.
Self-sampling has the potential to improve the ef-
fectiveness of the program in the Central Denmark
Region by increasing the overall participation by an
extra 2 to 5% among invited women. Furthermore, it
seems that self-sampling motivates hard-to-reach women
to re-engage with the screening program. A high compli-
ance with follow-up testing was seen. Offering non-
participating women the possibility of HPV self-sampling
as an alternative to regular cytology screening should be
considered.
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